皮肤鳞状细胞癌生物治疗的进展

doi:10.35541/cjd.20220172

中华皮肤科杂志 ›› 2022, e20220172.doi: 10.35541/cjd.20220172

皮肤鳞状细胞癌生物治疗的进展

吉祥,王大光

南京医科大学第一附属医院皮肤科，南京 210029

收稿日期:2022-03-15 修回日期:2022-08-26 发布日期:2022-11-11
通讯作者: 王大光 E-mail:wangirwin@126.com
基金资助:
国家自然科学基金（81000703、81472896）；江苏省自然科学基金（BK2009437）；江苏省六大人才高峰C类资助项目（2015-WSW-026）

Biotherapy for cutaneous squamous cell carcinoma

Ji Xiang, Wang Daguang

Department of Dermatology and Venereology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China

Received:2022-03-15 Revised:2022-08-26 Published:2022-11-11
Contact: Wang Daguang E-mail:wangirwin@126.com
Supported by:
National Natural Science Foundation of China （81000703, 81472896）; Natural Science Foundation of Jiangsu Province （BK2009437）; Six Talent Peaks of Jiangsu Province （2015-WSW-026）

摘要/Abstract

摘要： 【摘要】自2018年cemiplimab经美国食品药品管理局批准上市以来，抗程序性细胞死亡受体1抗体逐渐成为晚期皮肤鳞状细胞癌患者系统用药的一线选择。本文综述了目前皮肤鳞状细胞癌靶向治疗、免疫治疗、靶向/免疫联合治疗和基因治疗相关药物的临床应用。

关键词: 癌, 鳞状细胞, 皮肤, 分子靶向治疗, 免疫疗法, 生物治疗

Abstract: 【Abstract】 Since cemiplimab was approved by United States Food and Drug Administration in 2018, anti-programmed cell death receptor-1 antibodies have been considered as the first-line systemic therapy for advanced cutaneous squamous cell carcinoma. This review focuses on current clinical application of targeted therapy, immunotherapy, targeted immunotherapy and gene therapy in cutaneous squamous cell carcinoma.

Key words: Carcinoma, squamous cell, Skin, Molecular targeted therapy, Immunotherapy, Biotherapy

吉祥王大光. 皮肤鳞状细胞癌生物治疗的进展[J]. 中华皮肤科杂志, 2022,e20220172. doi:10.35541/cjd.20220172

Ji Xiang, Wang Daguang. Biotherapy for cutaneous squamous cell carcinoma[J]. Chinese Journal of Dermatology,2022,e20220172. doi:10.35541/cjd.20220172

参考文献 40

［1］	Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 2. treatment［J］. Eur J Cancer, 2020,128:83⁃102. doi: 10.1016/j.ejca.2020.01.008.
［2］	Soura E, Gagari E, Stratigos A. Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available?［J］. Curr Opin Oncol, 2019,31（5）:461⁃468. doi: 10.1097/CCO.0000000000000566.
［3］	Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 1. epidemiology, diagnostics and prevention［J］. Eur J Cancer, 2020,128:60⁃82. doi: 10.1016/j.ejca.2020.01.007.
［4］	Dereure O, Missan H, Girard C, et al. Efficacy and tolerance of cetuximab alone or combined with chemotherapy in locally advanced or metastatic cutaneous squamous cell carcinoma: an open study of 14 patients［J］. Dermatology, 2016,232（6）:721⁃730. doi: 10.1159/000461578.
［5］	Maubec E, Petrow P, Scheer⁃Senyarich I, et al. Phase II study of cetuximab as first⁃line single⁃drug therapy in patients with unresectable squamous cell carcinoma of the skin［J］. J Clin Oncol, 2011,29（25）:3419⁃3426. doi: 10.1200/JCO.2010.34.1735.
［6］	Montaudié H, Viotti J, Combemale P, et al. Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study［J］. Oncotarget, 2020,11（4）:378⁃385. doi: 10.18632/oncotarget.27434.
［7］	Foote MC, McGrath M, Guminski A, et al. Phase II study of single⁃agent panitumumab in patients with incurable cutaneous squamous cell carcinoma［J］. Ann Oncol, 2014,25（10）:2047⁃2052. doi: 10.1093/annonc/mdu368.
［8］	Hourbeigt K, Ehret M, Visseaux L, et al. Efficacy and safety of panitumumab alone or in association with radiotherapy in unresectable cutaneous squamous cell carcinoma［J］. J Eur Acad Dermatol Venereol, 2020,34（12）:2789⁃2794. doi: 10.1111/ jdv.16465.
［9］	Marti A, Fauconneau A, Ouhabrache N, et al. Complete remission of squamous cell carcinoma after treatment with panitumumab in a patient with cetuximab⁃induced anaphylaxis［J］. JAMA Dermatol, 2016,152（3）:343⁃345. doi: 10.1001/jamadermatol. 2015.4134.
［10］	Glisson BS, Kim ES, Kies MS, et al. Phase II study of gefitinib in patients with metastatic/recurrent squamous cell carcinoma of the skin［J］. J Clin Oncol, 2006,24（18_suppl）:5531. doi: 10. 1200/jco.2006.24.18_suppl.5531.
［11］	William WN Jr, Feng L, Ferrarotto R, et al. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: a single⁃arm phase II clinical trial［J］. J Am Acad Dermatol, 2017,77（6）:1110⁃1113.e2. doi: 10.1016/j.jaad.2017.07.048.
［12］	Gold KA, Kies MS, William WN Jr, et al. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: a single⁃arm phase 2 clinical trial［J］. Cancer, 2018,124（10）:2169⁃2173. doi: 10.1002/cncr.31346.
［13］	Read WL, Brumund KT, Weisman RA, et al. Squamous cell carcinomas of the skin responsive to erlotinib: 5 cases［J］. JAAD Case Rep, 2015,1（3）:153⁃156. doi: 10.1016/j.jdcr.2015.02.014.
［14］	Cavalieri S, Perrone F, Miceli R, et al. Efficacy and safety of single⁃agent pan⁃human epidermal growth factor receptor （HER） inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer［J］. Eur J Cancer, 2018,97:7⁃15. doi: 10.1016/j.ejca.2018.04.004.
［15］	Jenni D, Karpova MB, Mühleisen B, et al. A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis［J］. ESMO Open, 2016,1（1）:e000003. doi: 10.1136/esmoopen⁃2015⁃000003.
［16］	Strickley JD, Spalding AC, Haeberle MT, et al. Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib［J］. Exp Hematol Oncol, 2018,7:20. doi: 10.1186/s40164⁃018⁃0111⁃z.
［17］	Cañueto J, Cardeñoso E, García JL, et al. Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma［J］. Br J Dermatol, 2017,176（5）:1279⁃1287. doi: 10.1111/bjd.14936.
［18］	Boutros A, Cecchi F, Tanda ET, et al. Immunotherapy for the treatment of cutaneous squamous cell carcinoma［J］. Front Oncol, 2021,11:733917. doi: 10.3389/fonc.2021.733917.
［19］	Rischin D, Khushalani NI, Schmults CD, et al. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow⁃up of outcomes and quality of life analysis［J］. J Immunother Cancer, 2021,9（8）:e002757. doi: 10.1136/jitc⁃2021⁃002757.
［20］	Migden MR, Khushalani NI, Chang A, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open⁃label, phase 2, single⁃arm trial［J］. Lancet Oncol, 2020,21（2）:294⁃305. doi: 10.1016/S1470⁃2045（19）30728⁃4.
［21］	Migden MR, Rischin D, Schmults CD, et al. PD⁃1 blockade with cemiplimab in advanced cutaneous squamous⁃cell carcinoma［J］. N Engl J Med, 2018,379（4）:341⁃351. doi: 10.1056/NEJMoa 1805131.
［22］	Hober C, Fredeau L, Pham⁃Ledard A, et al. Cemiplimab for locally advanced and metastatic cutaneous squamous⁃cell carcinomas: real⁃life experience from the French CAREPI study group［J］. Cancers （Basel）, 2021,13（14）:3547. doi: 10.3390/cancers13143547.
［23］	Strippoli S, Fanizzi A, Quaresmini D, et al. Cemiplimab in an elderly frail population of patients with locally advanced or metastatic cutaneous squamous cell carcinoma: a single⁃center real⁃life experience from Italy［J］. Front Oncol, 2021,11:686308. doi: 10.3389/fonc.2021.686308.
［24］	Grob JJ, Gonzalez R, Basset⁃Seguin N, et al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single⁃arm phase II trial （KEYNOTE⁃629）［J］. J Clin Oncol, 2020,38（25）:2916⁃2925. doi: 10.1200/JCO. 19.03054.
［25］	Maubec E, Boubaya M, Petrow P, et al. Phase II study of pembrolizumab as first⁃line, single⁃drug therapy for patients with unresectable cutaneous squamous cell carcinomas［J］. J Clin Oncol, 2020,38（26）:3051⁃3061. doi: 10.1200/JCO.19.03357.
［26］	Hughes B, Mendoza RG, Basset⁃Seguin N, et al. Health⁃related quality of life of patients with recurrent or metastatic cutaneous squamous cell carcinoma treated with pembrolizumab in KEYNOTE⁃629［J］. Dermatol Ther （Heidelb）, 2021,11（5）:1777⁃1790. doi: 10.1007/s13555⁃021⁃00598⁃6.
［27］	Blum V, Müller B, Hofer S, et al. Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases［J］. Eur J Dermatol, 2018,28（1）:78⁃81. doi: 10.1684/ejd.2017.3209.
［28］	Ramella Munhoz R, de Camargo VP, Nader Marta G, et al. Final results of CA209⁃9JC: a phase II study of first⁃line nivolumab in patients with advanced cutaneous squamous cell carcinoma［J］. J Clin Oncol, 2021,32（5_suppl）:S885. doi: 10.1016/j.annonc. 2021.08.1449.
［29］	Barrios DM, Do MH, Phillips GS, et al. Immune checkpoint inhibitors to treat cutaneous malignancies［J］. J Am Acad Dermatol, 2020,83（5）:1239⁃1253. doi: 10.1016/j.jaad.2020.03. 131.
［30］	Day F, Kumar M, Fenton L, et al. Durable response of metastatic squamous cell carcinoma of the skin to ipilimumab immunotherapy［J］. J Immunother, 2017,40（1）:36⁃38. doi: 10. 1097/CJI.0000000000000146.
［31］	García⁃Sancha N, Corchado⁃Cobos R, Bellido⁃Hernández L, et al. Overcoming resistance to immunotherapy in advanced cutaneous squamous cell carcinoma［J］. Cancers （Basel）, 2021,13（20）:5134. doi: 10.3390/cancers13205134.
［32］	Stevenson ML, Wang CQ, Abikhair M, et al. Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab［J］. JAMA Dermatol, 2017,153（4）:299⁃303. doi: 10.1001/jamadermatol.2016.5118.
［33］	Ferris RL, Lenz HJ, Trotta AM, et al. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation［J］. Cancer Treat Rev, 2018,63:48⁃60. doi: 10.1016/j.ctrv.2017.11.008.
［34］	Hober C, Jamme P, Desmedt E, et al. Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab［J］. Ther Adv Med Oncol, 2021,13:175883592 11015493. doi: 10.1177/17588359211015493.
［35］	Chen A, Ali N, Boasberg P, et al. Clinical remission of cutaneous squamous cell carcinoma of the auricle with cetuximab and nivolumab［J］. J Clin Med, 2018,7（1）:10. doi: 10.3390/jcm7010 010.
［36］	Sernicola A, Lampitelli S, Marraffa F, et al. Case report: cetuximab use in advanced cutaneous squamous cell carcinoma resistant to chemotherapy［J］. F1000Res, 2019,8:933. doi: 10. 12688/f1000research.19149.2.
［37］	Trivedi S, Srivastava RM, Concha⁃Benavente F, et al. Anti⁃EGFR targeted monoclonal antibody isotype influences antitumor cellular immunity in head and neck cancer patients［J］. Clin Cancer Res, 2016,22（21）:5229⁃5237. doi: 10.1158/1078⁃0432.CCR⁃15⁃2971.
［38］	Hsu E, Eton O, Patel AV, et al. Combining panitumumab with anti⁃PD⁃1 antibody in cutaneous squamous cell carcinoma of the head and neck after inadequate response to anti⁃PD⁃1 antibody alone［J］. J Drugs Dermatol, 2021,20（8）:901⁃904. doi: 10.36849/ JDD.6175.
［39］	Thai AA, Lim AM, Solomon BJ, et al. Biology and treatment advances in cutaneous squamous cell carcinoma［J］. Cancers （Basel）, 2021,13（22）:5645. doi: 10.3390/cancers13225645.
［40］	Nguyen TA, Offner M, Hamid O, et al. Complete and sustained remission of metastatic cutaneous squamous cell carcinoma in a liver transplant patient treated with talimogene laherparepvec［J］. Dermatol Surg, 2021,47（6）:820⁃822. doi: 10.1097/DSS. 0000000000002739.

[1]	陈虎艳王磊刘伊雯周君浩曹蕾. 安罗替尼治疗皮肤血管肉瘤1例[J]. 中华皮肤科杂志, 2024, 57(5): 462-463.
[2]	张元文孙从乾潘文东. 肉毒毒素在皮肤科的超适应证临床应用[J]. 中华皮肤科杂志, 2024, 57(5): 471-475.
[3]	张玉丽季双双石秀艳孟宪敏刘文慧王冲. 儿童面部获得性色素沉着斑7例[J]. 中华皮肤科杂志, 2024, 57(5): 458-460.
[4]	胡梦瑶李敏陈思涵魏雪翠陈宇杰徐松陈旭. 角质形成细胞表达的S100A8/A9在3种常见皮肤炎症损伤模式中调控效应差异的研究[J]. 中华皮肤科杂志, 2024, 57(5): 435-444.
[5]	中国“一带一路”皮肤病专病联盟分枝杆菌病研究联盟中国麻风防治协会皮肤性病检验与诊断分会. [开放获取] 中国皮肤结核临床诊疗专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 426-434.
[6]	Michèle Verschoore 牛悦青 Stéphane Commo Léopold Muller 魏宇昊甄雅贤刘玮. [开放获取] 中华医学会-欧莱雅中国人健康皮肤/毛发研究项目成果总结——皮肤篇[J]. 中华皮肤科杂志, 2024, 57(5): 464-467.
[7]	中国中西医结合学会皮肤性病学分会真菌学组中国耐药皮肤癣菌病诊治与防控工作组. 中国耐药皮肤癣菌感染诊治与防控专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 418-425.
[8]	周甜甜吴雪歌杨欢方晓蒋金秋陈静思罗晓燕王华. 儿童慢性自发性荨麻疹病因及严重程度相关因素分析[J]. 中华皮肤科杂志, 2024, 57(4): 324-330.
[9]	田静邓思思宋志强. 特应性与非特应性结节性痒疹患者临床特征比较[J]. 中华皮肤科杂志, 2024, 57(4): 331-337.
[10]	王艺萌吴雯婷张倩张春雷李薇薇. 肛周外生殖器部位原发性实性肿瘤389例临床和病理诊断分析[J]. 中华皮肤科杂志, 2024, 57(4): 316-323.
[11]	严汝帆廖洁月郭子瑜姚南周文玉罗帅寒天张桂英赵明. 天疱疮发病机制和靶向治疗的研究进展[J]. 中华皮肤科杂志, 2024, 57(4): 374-378.
[12]	宋雨晴杨楠刘琳琳冯子仪韩世新周梅娟. [开放获取] 皮肤磨削术治疗家族性良性慢性天疱疮6例临床观察[J]. 中华皮肤科杂志, 2024, 0(4): 20220278-e20220278.
[13]	洪永镇王倩梁俊琴. 二代测序技术在非遗传性皮肤病领域中的运用[J]. 中华皮肤科杂志, 2024, 0(3): 20220436-e20220436.
[14]	陈星宇姚煦. 中性粒细胞在炎症性皮肤病中的研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220865-e20220865.
[15]	陈玉沙汪盛. 遗传性光敏感性皮肤病[J]. 中华皮肤科杂志, 2024, 57(3): 279-282.

皮肤鳞状细胞癌生物治疗的进展

Biotherapy for cutaneous squamous cell carcinoma

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 40

相关文章 15

Metrics

本文评价

推荐阅读 10